1. severe liver disease (such as child pugh score ≥ c, ast\> 5 times the upper limit); severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less) 2. positive pregnancy or breastfeeding or pregnancy test; 3. in the 30 days before the screening assessment, have taken any experimental treatment drugs for covid-19 (including off-label, informed consent use or trial-related); 4. those with a history of thromboembolism, except for those caused by picc.

1. severe liver disease (such as child pugh score ≥ c, ast\> 5 times the upper limit); severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less) 2. positive pregnancy or breastfeeding or pregnancy test; 3. in the 30 days before the screening assessment, have taken any experimental treatment drugs for covid-19 (including off-label, informed consent use or trial-related); 4. those with a history of thromboembolism, except for those caused by picc.

severe liver disease (such as child pugh score ≥ c, ast> 5 times the upper limit); severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less) positive pregnancy or breastfeeding or pregnancy test; in the 30 days before the screening assessment, have taken any experimental treatment drugs for covid-19 (including off-label, informed consent use or trial-related); those with a history of thromboembolism, except for those caused by picc.

severe liver disease (such as child pugh score ≥ c, ast> 5 times the upper limit); severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less) positive pregnancy or breastfeeding or pregnancy test; in the 30 days before the screening assessment, have taken any experimental treatment drugs for covid-19 (including off-label, informed consent use or trial-related); those with a history of thromboembolism, except for those caused by picc.

1. severe liver disease (such as child pugh score ≥ c, ast> 5 times the upper limit); severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less) 2. positive pregnancy or breastfeeding or pregnancy test; 3. in the 30 days before the screening assessment, have taken any experimental treatment drugs for covid-19 (including off-label, informed consent use or trial-related); 4. those with a history of thromboembolism, except for those caused by picc.

1. severe liver disease (such as child pugh score ≥ c, ast> 5 times the upper limit); severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less) 2. positive pregnancy or breastfeeding or pregnancy test; 3. in the 30 days before the screening assessment, have taken any experimental treatment drugs for covid-19 (including off-label, informed consent use or trial-related); 4. those with a history of thromboembolism, except for those caused by picc.